Loading clinical trials...
Loading clinical trials...
A Phase 1 Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Fezolinetant Compared to Subjects With Normal Hepatic Function
Conditions
Interventions
fezolinetant
Locations
4
United States
Clinical Research of West Florida, Inc.
Clearwater, Florida, United States
Clinical Pharmacology of Miami, LLC
Miami, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
American Research Corporation
San Antonio, Texas, United States
Start Date
September 2, 2020
Primary Completion Date
March 22, 2021
Completion Date
March 22, 2021
Last Updated
October 17, 2024
NCT00104325
NCT07118891
NCT01399385
NCT07295717
NCT03807401
NCT07271693
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions